Cardamyst is supplied as a carton of 2 disposable nasal spray devices, each delivering 2 sprays containing a total of 70mg of etripamil.

Tolebrutinib is currently being reviewed by the Food and Drug Administration (FDA) for the treatment of non-relapsing secondary progressive multiple sclerosis (nrSPMS). A regulatory decision on the ...

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

Daybue Stix, a strawberry-flavored trofinetide powder mixable with water-based liquids, gains FDA approval for Rett syndrome treatment.

HealthDay News — Federal officials say the US Food and Drug Administration (FDA) is reviewing reports of possible deaths in adults and children following COVID-19 vaccination. Federal officials say ...

HealthDay News — Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems have been reported. The review covers Beyfortus (from Sanofi ...

The phase 3 MINT study evaluated inebilizumab, a CD-19 directed cytolytic antibody, in 238 patients with gMG, including those who were anti-AChR-Ab+ and anti-MuSK-Ab+.

GLP-1 RAs probably have little or no effect on risk for thyroid cancer, pancreatic cancer, breast cancer, or kidney cancer.

The FDA approval of berotralstat oral pellets offers a new prophylaxis option for children aged 2 years and older with hereditary angioedema.

Retatrutide treatment resulted in significant improvements in WOMAC pain scores and body weight compared with placebo in the TRIUMPH-4 trial.

Gepotidacin is an oral triazaacenaphthylene bacterial type II topoisomerase inhibitor approved based on data from the phase 3 EAGLE-1 study.

The rate of severe infections decreased from 2 infections to 0.2 infections per PYO after treatment with etuvetidigene autotemcel.